MaxCyte, Inc. Q3 2026 Earnings Call Summary
MaxCyte, Inc. (MXCT) Q3 2026 Earnings Call Transcript
MaxCyte (MXCT) Q3 2026 Earnings Call Transcript
MaxCyte Inc (MXCT) (Q3 2026) Earnings Call Highlights: Revenue Surges 49% as Accron Acquisition ...
MaxCyte Q3 Earnings Call Highlights
MaxCyte Q3 2026 Earnings Call Transcript
MaxCyte (NASDAQ:MXCT) Tops Q3 Estimates, Raises 2026 Revenue Outlook Ahead of Akron Bio Acquisition
MaxCyte to Acquire Akron Bio for $151.8 Million
MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
MaxCyte FY2026 Revenue expected to be more than $34.500M vs $32.211M Est
MaxCyte To Acquire Akron BioProducts From Arcline Investment Management For Total Consideration Of $151.8M, Comprising $105M In Cash And 20.6M MXCT Shares Worth ~$26.8M
MaxCyte Q3 EPS $(0.05) Beats $(0.08) Estimate, Sales $10.152M Beat $7.481M Estimate
MaxCyte 13D Filing Shows Liontrust Investment Partners Reports 4.9% Stake In The Co As Of October 30, 2026
MaxCyte to Participate in Three Upcoming Investor Conferences
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
MaxCyte Reports Preliminary Q3 Core Revenue Of ~$8.1M, Up 26% YoY; Raises FY26 Revenue Guidance To ~$34M, Core Business Revenue Outlook To ~$28M
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MaxCyte (MXCT) Q2 2026 Earnings Call Transcript
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.